Ionis Pharmaceuticals, Inc.
NASDAQIonis Pharmaceuticals heads into the week after Q1 earnings with a notable divergence: the Street is growing more bullish while shorts are methodically unwinding, leaving the stock's $74.83 close roughly 25% below where analysts think it should trade. The bullish analyst turn is the standout story this week. Morgan Stanley raised its price target from $95 to $130 — still…
Snapshot as of 9 May 2026
Ionis Pharmaceuticals heads into the week after Q1 earnings with a notable divergence: the Street is growing more bullish while shorts are methodically unwinding, leaving the stock's $74.83 close roughly 25% below…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for IONS — free to start on ORTEX.
Sign up for free →Open IONS on ORTEX